Clinical Trial Supplies Market

Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) Therapeutic Areas (Oncology, CNS, CVD, Infectious, Immunology) (2022 - 2026)

Report Code: PH 3772 Jul, 2021, by marketsandmarkets.com

[242 Pages Report] The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of clinical trials conducted globally. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.

Clinical Trial Supplies Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the Clinical Trial Supplies Market

Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. There has been a tremendous amount of effort put into developing new treatments and vaccines to cure the infection. Within a few weeks of research, companies started coming up with drugs and treatments to treat the infection.

Global Clinical Trial Supplies Market Dynamics

DRIVER: Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies

The pharmaceutical and biopharmaceutical sector is one of the biggest R&D spenders globally. In the last decade, the R&D expenditure of pharmaceutical and biopharmaceutical companies has risen considerably. This is expected to lead to a rise in the number of clinical trials conducted globally. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), PhRMA members have invested significantly in drug development efforts. Companies in the market are actively looking to support R&D efforts. A further increase in R&D spending in the coming years will significantly boost drug discovery and development activities, thus driving the demand for clinical trial supplies.

RESTRAINTS: High cost of drug development

Drug discovery and development involve high costs due to the high attrition rate of drug candidates in development. Since R&D for some rare diseases is very challenging and requires a specific group of people to conduct a clinical trial, drug R&D processes can be prone to failure.

Only 7 out of 100 cancer drugs that reach the clinical testing phase end up gaining regulatory approval; most drugs fail long before this point. From drug discovery through FDA approval, developing a new medicine, on average, takes 10–15 years and costs USD 2.6 billion. Less than 12% of candidates that make it to Phase I clinical trials are approved by the FDA. This is a key factor limiting the growth of the market.

OPPORTUNITY: R&D investments offer significant opportunities for the market

North America and Europe, traditionally the major hubs for clinical trials, are facing challenges in terms of trial costs and patient pools. Recent health reforms in the US, the patent expiry of blockbuster drugs, and the global economic slowdown have affected the profitability of pharmaceutical companies. This is compelling several pharmaceutical companies to look for opportunities in emerging countries across the APAC, such as India, Singapore, South Korea, and China, which offer advantages such as reduced costs and easy access to a large heterogeneous patient population. Collaborations or expansions between companies in this market indicate that they are moving towards emerging markets to help their clients reduce the overall time consumed in clinical trials, thereby reducing their overall cost and resulting in the earlier launch of products in the market (post regulatory clearance). CROs can exploit these opportunities by supporting pharmaceutical companies to fulfill their needs for clinical trial supplies.

The Oncology segment dominated the clinical trial supplies market in 2020:

Based on the therapeutic area, the market is segmented into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology) Oncology is the largest segment in this market owing to the high and growing number of research studies on cancer therapeutics and the increasing number of companies focusing on bringing innovative cancer drugs into the market. Considering the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting innovative diagnostic and therapeutic approaches. In this scenario, effective drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors, many pharmaceutical companies are making significant investments in the development of innovative cancer drugs.

The pharmaceutical and biotechnology companies segment accounted for the largest share in 2020

Based on end users, the clinical trial supplies market is categorized into three segments—pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. The pharmaceutical and biotechnology companies accounted for the largest share of 70% of this market in 2020. This share is attributed to the rising R&D efforts by these companies.

Clinical Trial Supplies Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for clinical trial supplies in 2020.

Geographically, the market is segmented into North America, Europe, Asia Pacific, RoW. In 2020, North America accounted for the largest share of the clinical trial supplies market, followed by Europe & Asia Pacific. The growing number of registered clinical trials and significant investments in R&D for clinical trials in this region are major factors driving the growth of the North American market. The presence of many global pharmaceutical giants, such as Pfizer, Abbott Laboratories, and Johnson & Johnson (which outsource their clinical trials to reduce the costs and time associated with completing these trials) in this region is another key driver for market growth.

Key Market Players

Key players in the clinical trial supplies market include Thermo Fisher Scientific (US), Catalent, Inc. (US), Parexel (US), Almac Group (UK), Marken (US), Piramal Pharma Solutions (India), UDG Healthcare (Ireland).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Services, Phase, Therapeutic area, End user, Type and Region

Geographies covered

North America, Europe, Asia Pacific, Rest of the World

Companies covered

Thermo Fisher (US), Catalent, Inc. (US), Parexel (US), Eurofins (France) UDG Healthcare (Ireland), Piramal Pharma Solutions (India), Almac Group (UK), PCI Pharma Services (US), PRA Health Sciences (US), Biocair (UK), Eurofins (France), Marken (US), Infosys (India), Liveo Research (India), Capsugel (a Lonza Group company) (Switzerland), SIRO Clinpharm (India), KLIFO A/S (Denmark), Clinigen (UK), Ancillare (US), N-SIDE (Belgium), ADAllen (UK), Rubicon (India), Durbin (UK), Recipharm (Sweden), Seveillar (India), Myonex (India)

This report categorizes the global market into the following segments and subsegments:

Clinical Trial Supplies Market, by Services

  • Logistics & distribution
  • Storage & retention
  • Packaging, labeling, and blinding
  • Manufacturing
  • Comparator sourcing
  • Other services (solutions, ancillary supply)

Clinical Trial Supplies Market, by phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • BA/ BE studies

Clinical Trial Supplies Market, by type

  • Small molecules
  • Biologic drugs
  • Medical devices

Clinical Trial Supplies Market, by therapeutic area

  • Oncology
  • CNS and mental disorders
  • Cardiovascular diseases
  • Digestive disorders
  • Infectious diseases
  • Metabolic disorders
  • Immunology
  • Blood disorders
  • Other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology)

Clinical Trial Supplies Market, by end user

  • Pharmaceutical & Biotechnology companies
  • Contract Research Organisations (CROs)
  • Medical Devices Companies

Clinical Trial Supplies Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Singapore
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)
    • Latin America
    • Middlle East and Africa

Recent Developments

  • In April 2021, Thermo Fisher announced plans to acquire PPD for USD 17.4 billion to enhance its offerings in clinical research services and to support clinical trials
  • In April 2021, Parexel collaborated with Veeva Systems to improve their clinical processes for clinical trial delivery and enhance Veeva’s cloud technology

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 38)
    2.1 RESEARCH APPROACH
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET
           2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
                    FIGURE 3 DATA TRIANGULATION METHODOLOGY
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
           FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP-DOWN APPROACH)
           FIGURE 6 GLOBAL MARKET: FINAL MARKET SIZE (USD BILLION)
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
           FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
           FIGURE 8 FINAL CAGR PROJECTIONS (2021−2026)
    2.4 INSIGHTS FROM PRIMARIES
           FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.5 RESEARCH ASSUMPTIONS
    2.6 RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 46)
    FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2020 VS. 2026
    FIGURE 11 MARKET SHARE, BY SERVICE, 2020
    FIGURE 12 MARKET, BY PHASE, 2021 VS. 2026
    FIGURE 13 MARKET SHARE, BY THERAPEUTIC AREA, 2020
    FIGURE 14 MARKET SHARE, BY END USER, 2020
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
           FIGURE 16 INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET SHARE, BY TYPE & COUNTRY (2020)
           FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN NORTH AMERICA
    4.3 GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    5.3 IMPACT ANALYSIS
           5.3.1 DRIVERS
                    5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies
                               TABLE 2 R&D EXPENDITURE OF LEADING PHARMACEUTICAL COMPANIES IN 2019
                               FIGURE 20 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020)
                               FIGURE 21 GLOBAL R&D SPENDING (2016–2020)
                    5.3.1.2 Increasing number of registered clinical trials
                               FIGURE 22 NUMBER OF CLINICAL TRIALS IN THE LAST 10 YEARS
                    5.3.1.3 Increasing decentralization of clinical trials
           5.3.2 RESTRAINTS
                    5.3.2.1 High cost of drug development
           5.3.3 OPPORTUNITIES
                    5.3.3.1 Emerging markets
    5.4 RANGES/SCENARIOS
           FIGURE 23 DEPENDING ON HOW UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE MARKET
    5.5 COVID-19 IMPACT ANALYSIS
           FIGURE 24 NUMBER OF CLINICAL TRIALS, BY PHASE (2020–2021)
           FIGURE 25 NUMBER OF CLINICAL TRIALS, BY COUNTRY
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           FIGURE 26 PRE-COVID-19 VS. POST-COVID-19 SCENARIO
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 27 VALUE CHAIN ANALYSIS OF THE MARKET
    5.8 ECOSYSTEM/MARKET MAP
    5.9 SUPPLY CHAIN
    5.10 PORTER’S FIVE FORCES ANALYSIS
           5.10.1 PORTER’S 5 FORCES IMPACT ON THE CLINICAL TRIAL SUPPLIES MARKET
                    5.10.1.1 Threat from new entrants
                    5.10.1.2 Threat from substitutes
                    5.10.1.3 Bargaining power of suppliers
                    5.10.1.4 Bargaining power of buyers
                    5.10.1.5 Degree of competition
    5.11 REGULATORY LANDSCAPE
           5.11.1 INTRODUCTION

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE (Page No. - 68)
    6.1 INTRODUCTION
           TABLE 3 MARKET, BY SERVICE, 2019–2026 (USD MILLION)
    6.2 LOGISTICS & DISTRIBUTION
           6.2.1 INCREASING COMPLEXITY, EVOLVING TREATMENT PROTOCOLS, TECHNOLOGICAL ADVANCEMENTS, AND DATA SECURITY CHALLENGES TO DRIVE THE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES
                    TABLE 4 MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 5 NORTH AMERICA: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 6 EUROPE: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 7 APAC: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 STORAGE & RETENTION
           6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH IN THE STORAGE & RETENTION SERVICES MARKET SEGMENT
                    TABLE 8 MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 9 NORTH AMERICA: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 10 EUROPE: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 11 APAC: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 PACKAGING, LABELING, AND BLINDING
           6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE THIS MARKET SEGMENT.
                    TABLE 12 MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 13 NORTH AMERICA: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 14 EUROPE: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 15 APAC: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
    6.5 MANUFACTURING
           6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH
                    TABLE 16 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 17 NORTH AMERICA: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 18 EUROPE: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 19 APAC: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
    6.6 COMPARATOR SOURCING
           6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, INCREASING NUMBER OF CO-THERAPIES, AND THE RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH IN THIS SEGMENT
                    TABLE 20 MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 21 NORTH AMERICA: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 22 EUROPE: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 23 APAC: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
    6.7 OTHER SERVICES
           TABLE 24 MARKET FOR OTHER SERVICES, BY REGION, 2019–2026 (USD MILLION)
           TABLE 25 NORTH AMERICA: MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 26 EUROPE: MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 27 APAC: MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION)

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE (Page No. - 82)
    7.1 INTRODUCTION
           TABLE 28 MARKET, BY PHASE, 2019–2026 (USD MILLION)
    7.2 PHASE III
           7.2.1 SINCE PHASE III TRIALS INVOLVE A LARGE PATIENT POPULATION, THE DEMAND FOR OUTSOURCING OF CLINICAL TRIAL SUPPLIES IS HIGH IN THIS PHASE
                    TABLE 29 MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 30 NORTH AMERICA: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 31 EUROPE: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 32 APAC: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 PHASE II
           7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING THE EFFECTIVENESS OF THE DRUG AND FURTHER EVALUATING ITS SAFETY—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 33 MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 34 NORTH AMERICA: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 35 EUROPE: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 36 APAC: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 PHASE I
           7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY A VITAL ROLE IN PHASE I CLINICAL TRIALS
                    TABLE 37 MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 38 NORTH AMERICA: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 39 EUROPE: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 40 APAC: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 PHASE IV
           7.5.1 THESE STUDIES PRIMARILY ALLOW RESEARCHERS TO FIND AND OBSERVE THE LONG-TERM EFFECTS OF A PARTICULAR DRUG IN A CONSIDERABLY LARGER POOL OF PATIENTS—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 41 MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 42 NORTH AMERICA: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 43 EUROPE: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 44 APAC: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 BA/BE STUDIES
           7.6.1 INCREASING PATENT EXPIRATION TO INCREASE THE DEMAND FOR BA/BE STUDIES
                    TABLE 45 MARKET FOR BA/BE STUDIES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 47 EUROPE: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 48 APAC: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION)

8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE (Page No. - 93)
    8.1 INTRODUCTION
           TABLE 49 MARKET, BY TYPE, 2019–2026 (USD MILLION)
    8.2 SMALL-MOLECULE DRUGS
           8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH
                    TABLE 50 MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 51 NORTH AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 52 EUROPE: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 53 APAC: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 BIOLOGIC DRUGS
           8.3.1 BIOLOGIC DRUGS HAVE A RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 54 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 55 NORTH AMERICA: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 56 EUROPE: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 57 APAC: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 MEDICAL DEVICES
           8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET GROWTH
                    TABLE 58 MARKET FOR MEDICAL DEVICES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 61 APAC: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA (Page No. - 100)
    9.1 INTRODUCTION
           TABLE 62 MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
    9.2 ONCOLOGY
           9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH
                    TABLE 63 MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 65 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 66 APAC: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 CNS & MENTAL DISORDERS
           9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET GROWTH
                    TABLE 67 CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 68 NORTH AMERICA: MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 70 APAC: MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 CARDIOVASCULAR DISEASES
           9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH IN THIS MARKET SEGMENT
                    TABLE 71 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 74 APAC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 DIGESTIVE DISORDERS
           9.5.1 INCREASING R&D FOR THE DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES FOR THIS THERAPEUTIC AREA
                    TABLE 75 MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 76 NORTH AMERICA: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 78 APAC: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.6 INFECTIOUS DISEASES
           9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 HAS ACCELERATED THE EFFORTS TO DEVELOP NEW DRUGS—THIS WILL DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES
                    TABLE 79 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 80 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 81 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 82 APAC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.7 METABOLIC DISORDERS
           9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH IN THE COMING YEARS
                    FIGURE 28 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
                    TABLE 83 MARKET FOR METABOLIC DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 84 NORTH AMERICA: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 85 EUROPE: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 86 APAC: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.8 BLOOD DISORDERS
           9.8.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO BOOST THE PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS
                    TABLE 87 MARKET FOR BLOOD DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 90 APAC: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.9 IMMUNOLOGY
           9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL THE NEED FOR PROCURING CLINICAL TRIAL SUPPLIES
                    TABLE 91 MARKET FOR IMMUNOLOGY, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 92 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 93 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 94 APAC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.10 OTHER THERAPEUTIC AREAS
           TABLE 95 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 96 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 97 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 98 APAC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION)

10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER (Page No. - 120)
     10.1 INTRODUCTION
               TABLE 99 MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             10.2.1 INCREASING R&D INVESTMENTS TO BOOST THE OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECH COMPANIES
                       TABLE 100 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
                       TABLE 101 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 102 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 103 APAC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 CONTRACT RESEARCH ORGANIZATIONS
             10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE THE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
                       TABLE 104 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION)
                       TABLE 105 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 106 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 107 APAC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.4 MEDICAL DEVICE COMPANIES
             10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET GROWTH
                       TABLE 108 MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION)
                       TABLE 109 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 110 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 111 APAC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)

11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION (Page No. - 127)
     11.1 INTRODUCTION
               FIGURE 29 MARKET: GEOGRAPHICAL SNAPSHOT
               TABLE 112 MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
               FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
               TABLE 113 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 114 NORTH AMERICA: MARKET, BY SERVICE, 2019–2026 (USD MILLION)
               TABLE 115 NORTH AMERICA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
               TABLE 116 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
               TABLE 117 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
               TABLE 118 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                       11.2.1.1 Increasing R&D investments to drive market growth in the US
                                   TABLE 119 US: MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 120 US: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 121 US: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 122 US: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 123 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                       11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
                                   TABLE 124 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 125 CANADA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 126 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 127 CANADA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 128 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
               TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 130 EUROPE: MARKET, BY SERVICE, 2019–2026 (USD MILLION)
               TABLE 131 EUROPE: MARKET, BY PHASE, 2019–2026 (USD MILLION)
               TABLE 132 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
               TABLE 133 EUROPE: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
               TABLE 134 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                       11.3.1.1 Growing number of sponsored trials to boost the demand for clinical trial supplies in Germany
                                   TABLE 135 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 136 GERMANY: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 137 GERMANY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 138 GERMANY: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 139 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 UK
                       11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth to a certain extent
                                   TABLE 140 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 141 UK: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 142 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 143 UK: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 144 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                       11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France
                                   TABLE 145 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 146 FRANCE: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 147 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 148 FRANCE: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 149 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                       11.3.4.1 Increasing number of drug approvals to drive the market for clinical trial supplies in Italy
                                   TABLE 150 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 151 ITALY: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 152 ITALY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 153 ITALY: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 154 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                       11.3.5.1 Increasing biologics production to support market growth in Spain
                                   TABLE 155 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 156 SPAIN: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 157 SPAIN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 158 SPAIN: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 159 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.6 SWITZERLAND
                       11.3.6.1 Growing R&D efforts to provide growth opportunities for the clinical trial supplies market in Switzerland
                                   TABLE 160 SWITZERLAND: MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 161 SWITZERLAND: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 162 SWITZERLAND: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 163 SWITZERLAND: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 164 SWITZERLAND: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.7 REST OF EUROPE
                       TABLE 165 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                       TABLE 166 ROE: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                       TABLE 167 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 168 ROE: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                       TABLE 169 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
               FIGURE 31 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
               TABLE 170 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 171 APAC: MARKET, BY SERVICE, 2019–2026 (USD MILLION)
               TABLE 172 APAC: MARKET, BY PHASE, 2019–2026 (USD MILLION)
               TABLE 173 APAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
               TABLE 174 APAC: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
               TABLE 175 APAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 CHINA
                       11.4.1.1 Favorable government regulations are boosting the market growth in China
                                   TABLE 176 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 177 CHINA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 178 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 179 CHINA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 180 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 JAPAN
                       11.4.2.1 Government initiatives for drug innovation to support market growth in Japan
                                   TABLE 181 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 182 JAPAN: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 183 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 184 JAPAN: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 185 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                       11.4.3.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
                                   TABLE 186 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 187 INDIA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 188 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 189 INDIA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 190 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 AUSTRALIA
                       11.4.4.1 Australia has many research institutes conducting clinical trials—this is a key factor boosting the growth of the market
                                   TABLE 191 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 192 AUSTRALIA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 193 AUSTRALIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 194 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 195 AUSTRALIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.5 SOUTH KOREA
                       11.4.5.1 Government investments are a key contributor to market growth in South Korea
                                   TABLE 196 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 197 SOUTH KOREA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 198 SOUTH KOREA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 199 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 200 SOUTH KOREA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.6 SINGAPORE
                       11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore
                                   TABLE 201 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 202 SINGAPORE: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 203 SINGAPORE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 204 SINGAPORE: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 205 SINGAPORE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                       TABLE 206 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                       TABLE 207 ROAPAC: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                       TABLE 208 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 209 ROAPAC: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                       TABLE 210 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 ROW
               TABLE 211 ROW: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2019–2026 (USD MILLION)
             11.5.1 LATIN AMERICA
                       11.5.1.1 Growing R&D expenditure in the pharmaceutical and biopharmaceutical sector to drive market growth in Latin America
                                   TABLE 212 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 213 LATIN AMERICA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 214 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 215 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 216 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.5.2 MIDDLE EAST & AFRICA
                       11.5.2.1 Growing presence of pharmaceutical companies to drive market growth in the Middle East & Africa
                                   TABLE 217 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 218 MIDDLE EAST & AFRICA: MARKET, BY PHASE, 2019–2026 (USD MILLION)
                                   TABLE 219 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 220 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION)
                                   TABLE 221 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 181)
     12.1 INTRODUCTION
     12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
               FIGURE 32 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED
     12.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
               FIGURE 33 KEY PLAYERS IN THE GLOBAL MARKET
     12.4 MARKET SHARE ANALYSIS
               FIGURE 34 GLOBAL MARKET SHARE, BY KEY PLAYER, 2020
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                       FIGURE 35 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT, 2020
     12.6 GLOBAL MARKET: SME EVALUATION
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                       FIGURE 36 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR SMES, 2020
     12.7 COMPETITIVE BENCHMARKING
             12.7.1 COMPANY SERVICE FOOTPRINT (25 COMPANIES)
                       FIGURE 37 COMPANY PORTFOLIO FOOTPRINT: CLINICAL TRIAL SUPPLIES MARKET
                       TABLE 222 COMPANY REGION FOOTPRINT (25 COMPANIES)
                       TABLE 223 COMPANY SERVICE OFFERING FOOTPRINT (25 COMPANIES)
     12.8 GROWTH STRATEGIES ADOPTED BY MAJOR AND EMERGING PLAYERS
             12.8.1 GLOBAL MARKET: SERVICE LAUNCHES (JANUARY 2018 TO JUNE 2021)

13 COMPANY PROFILES (Page No. - 194)
     13.1 MAJOR PLAYERS
(Business Overview, Services Offered, Recent Developments, and Right to Win)*
             13.1.1 CATALENT, INC.
                       TABLE 224 CATALENT, INC.: BUSINESS OVERVIEW
                       FIGURE 38 CATALENT, INC.: COMPANY SNAPSHOT (2020)
             13.1.2 PAREXEL
                       TABLE 225 PAREXEL: BUSINESS OVERVIEW
             13.1.3 BIOCAIR
                       TABLE 226 BIOCAIR: BUSINESS OVERVIEW
             13.1.4 ALMAC GROUP
                       TABLE 227 ALMAC GROUP: BUSINESS OVERVIEW
             13.1.5 THERMO FISHER SCIENTIFIC
                       TABLE 228 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                       FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
             13.1.6 PIRAMAL PHARMA SOLUTIONS
                       TABLE 229 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
                       FIGURE 40 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2020)
             13.1.7 UDG HEALTHCARE
                       TABLE 230 UDG HEALTHCARE: BUSINESS OVERVIEW
                       FIGURE 41 UDG HEALTHCARE: COMPANY SNAPSHOT (2020)
             13.1.8 EUROFINS
                       TABLE 231 EUROFINS: BUSINESS OVERVIEW
                       FIGURE 42 EUROFINS: COMPANY SNAPSHOT (2020)
             13.1.9 MARKEN (A SUBSIDIARY OF UPS)
                       TABLE 232 UPS: BUSINESS OVERVIEW
                       FIGURE 43 UPS: COMPANY SNAPSHOT (2020)
             13.1.10 INFOSYS
                       TABLE 233 INFOSYS: BUSINESS OVERVIEW
                       FIGURE 44 INFOSYS: COMPANY SNAPSHOT (2020)
             13.1.11 PCI PHARMA SERVICES
                       TABLE 234 PCI PHARMA SERVICES: BUSINESS OVERVIEW
             13.1.12 PRA HEALTH SCIENCES
                       TABLE 235 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
                       FIGURE 45 PRA HEALTH SCIENCES: COMPANY SNAPSHOT (2019)
             13.1.13 LIVEO RESEARCH (FORMERLY BILCARE RESEARCH)
                       TABLE 236 BILCARE RESEARCH: BUSINESS OVERVIEW
                       FIGURE 46 BILCARE RESEARCH: COMPANY SNAPSHOT (2020)
             13.1.14 CAPSUGEL (ACQUIRED BY LONZA GROUP)
                       TABLE 237 LONZA GROUP: BUSINESS OVERVIEW
                       FIGURE 47 LONZA GROUP: COMPANY SNAPSHOT (2020)
* Business Overview, Services Offered, Recent Developments, and Right to Win might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS
             13.2.1 SIRO CLINPHARM
             13.2.2 KLIFO
             13.2.3 CLINIGEN
             13.2.4 ANCILLARE
             13.2.5 N-SIDE
             13.2.6 ADALLEN PHARMA
             13.2.7 RUBICON RESEARCH
             13.2.8 DURBIN
             13.2.9 RECIPHARM
             13.2.10 SEVEILLAR CLINICAL SUPPLIES SERVICES
             13.2.11 MYONEX (FORMERLY MYODERM)

14 APPENDIX (Page No. - 235)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global clinical trial supplies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global clinical trial supplies market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the demand side (such as personnel from pharmaceutical & biotechnology companies) and the supply side (such as clinical trial supply companies and pharmaceutical supply companies) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:

Clinical Trial Supplies Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the clinical trial supplies market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the clinical trial supplies business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global clinical trial supplies market based on type, therapeutic area, service, end user, phase, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, and opportunities)
  • To forecast the size of the market segments with respect to four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To profile key market players and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, service launches, expansions, partnerships, collaborations in the market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Clinical Trial Supplies Market Size,  Share & Growth Report
Report Code
PH 3772
Published ON
Jul, 2021
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status